Abstract
38 Effects of ADA on intracellular nucleoside triphosphate pools and implications for use in combination therapy : M.A. Ussery 1, H. Zhang 2, O.L. Wood 2, C. Pannecouque 3, E. De Clercq 3, and M. Witvrouw 3 1Innogenetics, Inc., Alpharetta, GA, USA, 2FDA, Rockville, MD, USA, and 3Rega Instit., Leuven, Belgium
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
